Bristol Myers Squibb has agreed to a very broad partnership with Hengrui Pharma, with the former company paying $600 million upfront to advance 13 early-stage development programs in both companies’ pipelines. The amount could reach as high as $15.2 billion.
The cost is $175 million in payments on the first and second anniversary of the agreement, which provides BMS with four oncology and hematology assets from Hengrui. BMS will be responsible for joint discovery and development of another five drug candidates. The total deal value includes option fees for the joint discovery programs and the successful completion of development, regulatory and commercial milestones for all of the programs.
BMS has granted Hengrui rights to four of its immunology assets in China, Hong Kong and Macau. BMS stated that the Shanghai-based biotech company will be fully responsible for early human development to expedite clinical proof of concept.
Access to tapping capabilities across geographies may enable BMS to achieve early clinical insights and promote informed decisions, said Robert Plenge, chief research officer at BMS. Among the contributions that Hengrui made to the partnership, it named “efficient early-stage development expertise.”
The comments seem to be a sign of evidence that in China, drugs reach clinical proof of concept faster. McKinsey discovered that the process of discovery to filing clinical trial registration in China takes between 50% and 70% less time than in other parts of the world.
BMS’ chief financial officer David Elkins recently admitted in December that China has the advantage at a Citi investor meeting. It’s “very crucial” to the development cycle to work in China to get the products into human beings as soon as possible to get to proof of concept, Elkins said. The CFO also said China was poised to become the world’s largest source of new clinical trials, beating the U.S.
The Hengrui collaboration provides BMS with pipeline programs and the ability to drive early development of some of these pipeline programs and a handful of BMS’ own candidates. Hengrui will have the opportunity to co-develop some of the assets and to participate in BMS’s global commercialization and regulatory processes, as well as its partners’ global R&D and regulatory and commercialization processes.
Unlike Hengrui’s other partnerships, BMS will include its own assets in the agreement. GSK signed one Hengrui candidate for $500 million upfront, and options on 11 more, last year. The agreement, valued up to $12 billion, required Hengrui to take the assets to phase 1. In addition, Hengrui has agreements with Kailera, Merck & Co., and Merck KGaA.
Hengrui Partners with Bristol Myers Squibb in Major Pharma Agreement
Hengrui has become part of a major strategic agreement after Bristol Myers Squibb signed a deal worth up to $15 billion to acquire selected Hengrui assets. The agreement highlights growing international interest in China’s rapidly expanding pharmaceutical research and development sector.
The pharmaceutical sector is increasingly witnessing cross-border partnerships aimed at accelerating innovation and expanding access to advanced research capabilities. International drugmakers are actively seeking opportunities in emerging biotech markets where scientific expertise, faster clinical development, and cost efficiencies provide competitive advantages.
The latest agreement represents one of the largest partnerships involving Chinese pharmaceutical assets in recent years. Analysts believe such collaborations are reshaping the global healthcare landscape and encouraging stronger international cooperation in drug discovery and commercialization.
Rising Influence of Chinese Biopharmaceutical Innovation
China’s biotechnology industry has evolved rapidly over the last decade, supported by government investment, improved regulatory systems, and growing scientific talent. Many Chinese pharmaceutical firms are now developing advanced therapies that compete on a global level, attracting interest from multinational healthcare companies.
The country has become an important hub for clinical trials, oncology research, and innovative medicine development. As a result, global pharmaceutical leaders are increasingly viewing Chinese biotech partnerships as essential components of future growth strategies.
